Tylvalosin offers distinct advantages over other macrolide antibiotics. It lacks complete cross-resistance with other macrolide antibiotics, effectively addressing bacterial and mycoplasma resistance to tylosin, tilmicosin, and azithromycin, as well as low blood concentrations. Its mechanism of action is similar to that of other macrolide antibiotics: it binds to the 50S subunit of the ribosome in susceptible bacteria, blocking transpeptidation and mRNA displacement, thereby inhibiting peptide synthesis and elongation, ultimately impacting bacterial protein synthesis. This unique mechanism of action holds broad promise for the application of tylosin in pig farming.